Phathom Pharmaceuticals Inc
PHAT
Market Cap$1.18B
Close$
$1.51
85.8% downside
Current Fair Value
85.8% downsideOvervalued by 85.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.18 Billion |
|---|---|
| Enterprise Value | $965.68 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.93 |
| Beta | 0.71 |
| Outstanding Shares | 58,558,145 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.4 |
|---|---|
| PEG | 3.4 |
| Price to Sales | 10.64 |
| Price to Book Ratio | -1.77 |
| Enterprise Value to Revenue | 11.8 |
| Enterprise Value to EBIT | -3.41 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Phathom Pharmaceuticals Inc
55 employeesPhathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, E...